| Not Yet Recruiting | Adoption of Audio Recording in the Outpatient Supportive Care Center NCT04871477 | M.D. Anderson Cancer Center | — |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refra NCT06620302 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Meta NCT06320405 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Soli NCT06126276 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Recruiting | Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study NCT06295965 | University of Washington | — |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors NCT05286801 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment NCT05455606 | SWOG Cancer Research Network | N/A |
| Withdrawn | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors NCT05010096 | M.D. Anderson Cancer Center | Phase 1 |
| Suspended | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors NCT04840589 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 | Children's Oncology Group | Phase 1 / Phase 2 |
| Active Not Recruiting | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors NCT05071209 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis NCT05059678 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of NCT05101356 | Tianhong Li | Phase 1 / Phase 2 |
| Active Not Recruiting | Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for P NCT04960787 | SWOG Cancer Research Network | N/A |
| Active Not Recruiting | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Car NCT04090619 | M.D. Anderson Cancer Center | — |
| Recruiting | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Suspended | Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supporti NCT05091632 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Can NCT05058339 | M.D. Anderson Cancer Center | — |
| Active Not Recruiting | Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Ad NCT04062552 | University of Rochester NCORP Research Base | N/A |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, NCT04693468 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tum NCT04530487 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers NCT04171219 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Active Not Recruiting | Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer NCT03927885 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Muta NCT03212274 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapse NCT03420963 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma NCT03502733 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Ad NCT03583255 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors NCT03366103 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers NCT03017833 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tu NCT03430882 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Insta NCT03428802 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors NCT03320330 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or L NCT03323034 | Children's Oncology Group | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patient NCT02975882 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02808650 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue i NCT03035409 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Can NCT02451553 | University of Washington | Phase 1 |
| Completed | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 | Children's Oncology Group | Phase 1 |
| Active Not Recruiting | Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Sol NCT02389309 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Collection and Storage of Tissue and Blood Samples From Patients With Cancer NCT02474160 | National Cancer Institute LAO | — |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors NCT02143401 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies NCT02116777 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus NCT01822522 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors NCT01709435 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770 | Children's Oncology Group | Phase 1 / Phase 2 |